Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (18588)	4/3/1998 10:57:00 PM
From: kha vu	Read Replies (1) \| Respond to of 32384

this is the excerpt from : investor.msn.com Ligand Pharmaceuticals (LGND) continues to please its big-pharma partners. SmithKline Beecham (SBH) has decided to expand its research and development program with Ligand for a second time. The new collaboration targets oral drugs to regulate the Leptin cytokine for the treatment and prevention of obesity. SmithKline has agreed to make another $5 million equity investment in Ligand at a 20% premium to recent market prices for the stock. SmithKline also paid an additional $1 million for a warrant exercisable at $20 a share. That has helped Ligand's stock maintain its very gradual upward momentum -- shares recently traded at $16. My 12-month target price for the stock is $24. this is the excerpt from : investor.msn.com